BioCentury
ARTICLE | Clinical News

Noxxon starts Phase I/II of olaptesed pegol, Keytruda combo in cancer

July 14, 2017 7:29 PM UTC

Noxxon Pharma N.V. (Euronext:ALNOX) began a 2-part Phase I/II trial to evaluate olaptesed pegol (NOX-A12) plus Keytruda pembrolizumab in about 10 patients with metastatic colorectal cancer and 10 patients with metastatic pancreatic cancer. Patients will receive 300 mg olaptesed pegol as monotherapy weekly for 2 weeks in part 1 and then 300 mg olaptesed pegol every 3 weeks in combination with Keytruda for up to 2 years in part 2.

The open-label, German trial's primary endpoints will evaluate safety and changes within the tumor microenvironment, including the number of T cells present. Secondary endpoints include disease control rate (DCR), progression-free survival (PFS) and overall survival (OS)...

BCIQ Company Profiles

TME Pharma N.V.